Breaking News Instant updates and real-time market news.

AERI

Aerie Pharmaceuticals

$38.85

-0.64 (-1.62%)

06:49
04/25/19
04/25
06:49
04/25/19
06:49

Aerie Pharmaceuticals: NDA for AR-13503 accepted by FDA

Aerie Pharmaceuticals announced that the U.S. FDA has reviewed the Investigational New Drug Application for AR-13503 and it is now in effect, allowing Aerie to initiate human studies in the treatment of neovascular age-related macular degeneration and diabetic macular edema. The IND was submitted in March. Aerie expects to initiate a first-in-human clinical study later in the second quarter.

  • 28

    Apr

  • 23

    May

AERI Aerie Pharmaceuticals
$38.85

-0.64 (-1.62%)

03/05/19
ADAM
03/05/19
NO CHANGE
Target $73
ADAM
Buy
Aerie Pharmaceuticals price target lowered to $73 from $86 at Canaccord
Canaccord analyst Dewey Steadman lowered his price target on Aerie Pharmaceuticals to $73 from $86 as Rhopressa data for the week ending February 22 showed mixed growth as very modest TRx growth did not translate into sequential bottle dispensing growth. The analyst said Rhopressa has been stuck on a plateau for the past few weeks and there needs to be a meaningful acceleration of dispensing for the company to meet expectations. Steadman maintained his Buy rating on Aerie Pharmaceuticals shares.
03/13/19
JMPS
03/13/19
NO CHANGE
Target $75
JMPS
Outperform
JMP Securities sees fast adoption for Aerie Pharmaceuticals' Rocklatan
After Aerie Pharmaceuticals announced that it received early FDA approval of Rocklatan, JMP Securities analyst Donald Ellis said he expects the drug to be quickly adopted by physicians and patients given its best-in-class efficacy and once-a-day dosing. Many physicians are already prescribing Rhopressa + PGA and he would expect many to switch to Rocklatan alone, added Ellis, who keeps an Outperform rating and $75 price target on Aerie shares.
03/19/19
ADAM
03/19/19
NO CHANGE
Target $65
ADAM
Buy
Aerie Pharmaceuticals price target cut to $65 from $73 at Canaccord
Canaccord analyst Dewey Steadman maintained a Buy rating on Aerie Pharmaceuticals and cut his price target to $65 from $73 after weekly Rhopressa data showed modest sequentially growth for the week ending March 8 after a strong prior week. In a research note to investors, Steadman says 10 weeks into the quarter, he is bringing down revenue estimates below consensus as he thinks volumes don't justify a $17M+ revenue estimate for the quarter.
03/21/19
PIPR
03/21/19
INITIATION
Target $80
PIPR
Overweight
Aerie Pharmaceuticals initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro started Aerie Pharmaceuticals with an Overweight rating and $80 price target. Rhopressa is off to a "nice start" in its first few quarters, and key opinion leader feedback indicates the recently approved Rocklatan has the potential to transform the glaucoma treatment landscape in the U.S., Catanzaro tells investors in a research note. He believes Aerie's glaucoma franchise has the potential to generate U.S. sales in excess of $800M by 2025 and expects the shares to appreciate as this revenue opportunity is realized.

TODAY'S FREE FLY STORIES

AKRO

Akero Therapeutics

$0.00

(0.00%)

11:34
06/20/19
06/20
11:34
06/20/19
11:34
Syndicate
Breaking Syndicate news story on Akero Therapeutics »

Akero Therapeutics opens…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

AKRO

Akero Therapeutics

$0.00

(0.00%)

11:32
06/20/19
06/20
11:32
06/20/19
11:32
Syndicate
Breaking Syndicate news story on Akero Therapeutics »

Akero Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

TYPE

Monotype Imaging

$17.90

1.41 (8.55%)

11:30
06/20/19
06/20
11:30
06/20/19
11:30
Recommendations
Monotype Imaging analyst commentary  »

Private equity buyer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EMLC

VanEck Vectors J.P. Morgan EM Local Currency Bond ETF

$34.54

0.27 (0.79%)

11:30
06/20/19
06/20
11:30
06/20/19
11:30
Options
Upside call buyer in thinly traded Emerging Markets Sovereign Debt ETF »

Upside call buyer in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WORK

Slack Technologies

$0.00

(0.00%)

11:29
06/20/19
06/20
11:29
06/20/19
11:29
Syndicate
Breaking Syndicate news story on Slack Technologies »

Slack Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKRO

Akero Therapeutics

$0.00

(0.00%)

11:28
06/20/19
06/20
11:28
06/20/19
11:28
Syndicate
Akero Therapeutics indicated to open at $16.76, IPO priced at $16.00 »

Akero Therapeutics (AKRO)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

11:25
06/20/19
06/20
11:25
06/20/19
11:25
General news
Oil Action: WTI crude advanced as much as 6% »

Oil Action: WTI crude…

QGEN

Qiagen

$41.02

0.34 (0.84%)

11:25
06/20/19
06/20
11:25
06/20/19
11:25
Conference/Events
Qiagen to host analyst & investor day »

Analyst & Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 06

    Aug

AIR

AAR Corp.

$33.83

0.125 (0.37%)

11:23
06/20/19
06/20
11:23
06/20/19
11:23
Hot Stocks
AAR, Tawazun Economic Council and GAL sign joint repair management deal »

AAR announced a new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

GO

Grocery Outlet

$0.00

(0.00%)

11:22
06/20/19
06/20
11:22
06/20/19
11:22
Syndicate
Breaking Syndicate news story on Grocery Outlet »

Grocery Outlet indicated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

WORK

Slack Technologies

$0.00

(0.00%)

11:20
06/20/19
06/20
11:20
06/20/19
11:20
Syndicate
Breaking Syndicate news story on Slack Technologies »

Slack Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNLN

Greenlane

$12.23

1.25 (11.38%)

11:19
06/20/19
06/20
11:19
06/20/19
11:19
Recommendations
Greenlane analyst commentary  »

Greenlane fundamentals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCL

Carnival

$47.60

-5.25 (-9.93%)

11:18
06/20/19
06/20
11:18
06/20/19
11:18
Downgrade
Carnival rating change  »

Carnival downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

CTST

CannTrust

$5.31

-0.05 (-0.93%)

, CURR

CURE Pharmaceutical

$0.00

(0.00%)

11:17
06/20/19
06/20
11:17
06/20/19
11:17
On The Fly
Rising High: CannTrust launches U.S. operations with California JV »

In this week's "Rising…

CTST

CannTrust

$5.31

-0.05 (-0.93%)

CURR

CURE Pharmaceutical

$0.00

(0.00%)

CGC

Canopy Growth

$43.05

0.275 (0.64%)

ACRGF

Acreage Holdings

$0.00

(0.00%)

TLRY

Tilray

$47.00

1.55 (3.41%)

IIPR

Innovative Industrial Properties

$135.35

10.335 (8.27%)

ORTFD

Biome Grow

$0.00

(0.00%)

APHA

Aphria

$6.75

0.01 (0.15%)

ACB

Aurora Cannabis

$7.46

-0.025 (-0.33%)

MMNFF

MedMen

$0.00

(0.00%)

ORHOF

Origin House

$0.00

(0.00%)

KSHB

KushCo Holdings

$0.00

(0.00%)

CRON

Cronos Group

$16.50

0.655 (4.14%)

MLCPF

MediPharm Labs

$0.00

(0.00%)

CVSI

CV Sciences

$0.00

(0.00%)

CANN

General Cannabis

$0.00

(0.00%)

IGC

India Globalization Capital

$1.32

0.09 (7.32%)

KNHBF

ICC International Cannabis

$0.00

(0.00%)

NDVAF

INDIVA

$0.00

(0.00%)

OGRMF

Organigram

$0.00

(0.00%)

ELLXF

Elixinol Global

$0.00

(0.00%)

PLNHF

Planet 13 Holdings

$0.00

(0.00%)

MRRCF

Wayland Group

$0.00

(0.00%)

KHRNF

Khiron Life Sciences

$0.00

(0.00%)

LHSIF

Liberty Health Sciences

$0.00

(0.00%)

SNNVF

Sunniva

$0.00

(0.00%)

HMDEF

DionyMed Brands

$0.00

(0.00%)

SRUTF

Sproutly

$0.00

(0.00%)

GRWG

Grow Generation

$0.00

(0.00%)

HRVSF

Harvest Health & Recreation

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 21

    Jun

  • 25

    Jun

  • 26

    Jun

  • 27

    Jun

  • 28

    Jun

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
06/20/19
06/20
11:17
06/20/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
06/20/19
06/20
11:16
06/20/19
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KKR

KKR

$24.52

0.23 (0.95%)

11:15
06/20/19
06/20
11:15
06/20/19
11:15
Options
KKR put volume heavy and directionally bearish »

Bearish flow noted in KKR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
06/20/19
06/20
11:15
06/20/19
11:15
General news
Treasury announced a $113 B in coupon sales for next week »

Treasury announced a $113…

11:15
06/20/19
06/20
11:15
06/20/19
11:15
General news
Breaking General news story  »

4-Week Bill Auction to be…

11:15
06/20/19
06/20
11:15
06/20/19
11:15
General news
Breaking General news story  »

8-Week Bill Auction to be…

BGNE

BeiGene

$124.98

4.98 (4.15%)

11:09
06/20/19
06/20
11:09
06/20/19
11:09
Hot Stocks
BeiGene announces Phase 1b results of zanubrutinib with Gazyva »

BeiGene announced results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

PSNL

Personalis

$0.00

(0.00%)

11:09
06/20/19
06/20
11:09
06/20/19
11:09
Syndicate
Breaking Syndicate news story on Personalis »

Personalis indicated to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

AMRN

Amarin

$19.82

0.4 (2.06%)

11:08
06/20/19
06/20
11:08
06/20/19
11:08
On The Fly
Jefferies sees Amarin stock poised for even more gains »

Seeing the stock's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

STLD

Steel Dynamics

$29.25

-0.45 (-1.52%)

11:05
06/20/19
06/20
11:05
06/20/19
11:05
Options
Steel Dynamics call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSON

Misonix

$23.52

(0.00%)

11:04
06/20/19
06/20
11:04
06/20/19
11:04
Hot Stocks
Breaking Hot Stocks news story on Misonix »

Misonix up 39c to $24.17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.